Nivolumab after recurrent pembrolizumab-associated hepatotoxicity in PD-L1-high metastatic squamous non-small cell lung cancer: a case report
Oxford Medical Case Reports · 03.08.2026 · 2026 (8)
DOI: 10.1093/omcr/omag159 ↗Kurz gefasst
Fallbericht in der Zeitschrift Oxford Medical Case Reports, online erschienen am 22.08.2026. Verfasst von Adam Bowen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, McLaren Greater Lansing Hospital, Michigan State University, 2900 Collins Rd, Lansing, MI 48910, United States. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune-related hepatitis can interrupt effective PD-1 therapy, and evidence guiding within-class retreatment after recurrent toxicity remains limited. An 82-year-old woman with remote resected lung cancer later developed PD-L1-high metastatic squamous non-small cell lung cancer with thoracic and hepatic disease. After 4 pembrolizumab doses, mixed liver injury developed despite normal baseline liver chemistries. Viral hepatitis serologies were negative, liver ultrasound was unrevealing, and acetaminophen exposure remained a non-significant competing factor. Liver tests improved with corticosteroids but recurred after 2 pembrolizumab rechallenges, including a grade 3 event, prompting permanent discontinuation. Nivolumab was started after biochemical recovery and was tolerated for more than 3 years without recurrent hepatotoxicity. Follow-up PET-CT demonstrated durable metabolic resolution of thoracic and hepatic disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, McLaren Greater Lansing Hospital, Michigan State University, 2900 Collins Rd, Lansing, MI 48910, United States.
- Department of Hematology/Oncology, Karmanos Cancer Institute at McLaren Greater Lansing Hospital, Michigan State University, 3520 Forest Rd, Lansing, MI 48910, United States.
ORCID-Profile: Adam Bowen
Zitieren
APA
Bowen, A., Wendel, K., Saleem, M. D., Lin, Z., Thulluri, R., & Hrinczenko, B. (2026). Nivolumab after recurrent pembrolizumab-associated hepatotoxicity in PD-L1-high metastatic squamous non-small cell lung cancer: a case report. Oxford Medical Case Reports, 2026(8). https://doi.org/10.1093/omcr/omag159
Vancouver
Bowen A, Wendel K, Saleem MD, Lin Z, Thulluri R, Hrinczenko B. Nivolumab after recurrent pembrolizumab-associated hepatotoxicity in PD-L1-high metastatic squamous non-small cell lung cancer: a case report. Oxford Medical Case Reports. 2026;2026(8). doi:10.1093/omcr/omag159
BibTeX
@article{Bowen2026,
author = {Bowen, Adam and Wendel, Katlyn and Saleem, Muhammad-Danish and Lin, Zijin and Thulluri, Ramalakshmi and Hrinczenko, Borys},
title = {Nivolumab after recurrent pembrolizumab-associated hepatotoxicity in PD-L1-high metastatic squamous non-small cell lung cancer: a case report},
journal = {Oxford Medical Case Reports},
year = {2026},
volume = {2026},
number = {8},
doi = {10.1093/omcr/omag159}
}
EUVIMED